Nonclinical evaluation of renizgamglogene autogedtemcel for SCD and TDT
Authors:
Open Access
- 24 September 2025
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 34 (1) , 249-265
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell diseaseMolecular Therapy, 2024
- Exagamglogene Autotemcel: First ApprovalMolecular Diagnosis & Therapy, 2024
- Kinetic Basis for DNA Target Specificity of CRISPR-Cas12aMolecular Cell, 2018
- Oxygen‐dependent flow of sickle trait blood as an in vitro therapeutic benchmark for sickle cell disease treatmentsAmerican Journal of Hematology, 2018
- Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin SwitchCell, 2018
- Developmentally‐faithful and effective human erythropoiesis in immunodeficient and Kit mutant miceAmerican Journal of Hematology, 2017
- Improved Human Erythropoiesis and Platelet Formation in Humanized NSGW41 MiceStem Cell Reports, 2016
- Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas SystemCell, 2015
- Genotype–phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in IranInternational Journal of Hematology, 2011
- [3] Detection of globin chains by reversed-phase high-performance liquid chromatography1994